Reference
Barbanti P et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 22:46. https://doi.org/10.1186/s10194-022-01396-x
The Journal of Headache and Pain volume 23, Article number: 51 (2022)
Correction to: J Headache Pain 22, 46 (2022)
https://doi.org/10.1186/s10194-022-01396-x
Following the publication of the original article [1], we were notified that the name of the 9th author was incorrectly spelled as Massimo FilippiBonassi, instead of Massimo Filippi.
The original article has been corrected.
Barbanti P et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 22:46. https://doi.org/10.1186/s10194-022-01396-x
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Barbanti, P., Egeo, G., Aurilia, C. et al. Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23, 51 (2022). https://doi.org/10.1186/s10194-022-01422-y
Published:
DOI: https://doi.org/10.1186/s10194-022-01422-y